Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Mounjaro (tirzepatide) and Victoza (liraglutide) are both FDA-approved to treat type 2 diabetes, while Zepbound (tirzepatide) and Saxenda (liraglutide) are FDA-approved specifically for weight loss
For receptor attribution studies: MC1R-selective antagonists to isolate melanogenesis biology, MC4R-selective antagonists to isolate pro-sexual and anorectic biology, and MT-1 parallel groups to characterise the additional central effects produced by cyclisation
Early detection makes treatment much more effective
This leads to: Increased insulin secretion when glucose is present Decreased glucagon secretion Delayed gastric emptying Reduced appetite and caloric intake These combined effects help improve glycemic control and promote weight loss
Tirzepatide 15 mg is the most effective peptide for weight loss in overweight individuals without type 2 diabetes, according to a study published in The New England Journal of Medicine on May 11, 2025
US$ 22.66
US$ 28.27
US$ 26.28
US$ 20.42
US$ 23.85
US$ 27.65
US$ 27.23
US$ 23.19
US$ 22.60
US$ 24.91
